GlassScriptPhysician profile
Gerardo Lanes
NPI 1033182605
$3,741.82
in general payments reported to CMS, 2019-2025
30 companies · $964 in 2025
The $964 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $921 · 2020: $285 · 2021: $178 · 2022: $181 · 2023: $537 · 2024: $677 · 2025: $964.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,161 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,161.18 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $673.28 | 2019-2025 | |
| Janssen Biotech, INC. | $408.27 | 2019-2025 | Tremfya, Stelara, Simponi |
| Gilead Sciences, INC. | $357.63 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $311.26 | 2019-2025 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $300.21 | 2019-2025 | Xifaxan |
| Madrigal Pharmaceuticals | $203.44 | 2024-2025 | Rezdiffra, Resmetirom |
| Celgene Corporation | $181.47 | 2021-2024 | Zeposia |
| Genzyme Corporation | $140.17 | 2022-2025 | |
| Allergan, INC. | $134.51 | 2019 | |
| Phathom Pharmaceuticals, INC. | $132.28 | 2023-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $116.07 | 2020-2024 | |
| Ardelyx, INC. | $106.98 | 2022-2025 | Ibsrela |
| Redhill Biopharma INC. | $103.17 | 2020-2022 | |
| Qol Medical, LLC | $68.21 | 2023 | Sucraid |
| Merck Sharp & Dohme LLC | $53.75 | 2023-2024 | Dificid |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $53.74 | 2023-2024 | Dupixent |
| Lilly USA, LLC | $48.03 | 2024-2025 | Omvoh |
| Shionogi INC | $46.04 | 2019 | |
| Nestle Healthcare Nutrition INC. | $45.02 | 2020-2023 | |
| Johnson & Johnson Health Care Systems INC. | $42.97 | 2019 | |
| Intercept Pharmaceuticals, INC. | $38.06 | 2019 | |
| Pharmacosmos Therapeutics INC. | $27.88 | 2023 | Monoferric |
| Aimmune Therapeutics, INC. | $25.21 | 2025 | Zenpep |
| Otsuka America Pharmaceutical, INC. | $24.62 | 2019 | |
| Daiichi Sankyo INC. | $24.07 | 2019 | |
| Evoke Pharma, INC. | $19.66 | 2023 | Gimoti |
| Fujifilm Healthcare Americas Corporation | $19.57 | 2022 | |
| Braintree Laboratories, INC. | $17.77 | 2020 | |
| Shire North American Group INC | $15.87 | 2019 | |
| Micro-Tech Endoscopy USA, INC. | $2.61 | 2024 | Dat Device |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerardo Lanes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.